Clinical trial NCT00673673: FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Official title: Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gastroesophageal Cancer
Gastric Cancer
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2008-05-07
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically documented recurrent, metastatic or unresectable gastroesophageal (Siewert type I, II, III) or gastric adenocarcinoma with measurable or assessable non-measurable disease (RECIST criteria).
* If recurrent or metastatic disease is not histologically confirmed, then documentation by a second radiographic procedure (i.e., PET scan or MRI in addition to CT scan) is required. If the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation is required
* 12 months since completion of any prior neoadjuvant or adjuvant therapy (chemotherapy or radiotherapy) for potentially resectable gastroesophageal or gastric adenocarcinoma.
* \>4 weeks since major surgery.
* ECOG Performance Status: 0-1
* Life expectancy \>12 weeks
* Laboratory parameters as follows: absolute neutrophil count ≥1,500/uL, platelet count ≥100,000/uL, hemoglobin ≥9 g,/dL, creatinine \<1.5 X ULN or estimated GFR \>30 ml's/min, urinalysis \<2+ protein, baseline proteinuria \<1000 mg/d or urine protein/creatinine ratio \<1, bilirubin \<2 X ULN, PT (INR) \<1.5 if patient not on anticoagulation, negative pregnancy test in women of childbearing age
* Hypertension must be well controlled (\<160/90)
* Paraffin block or slides must be available
* Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of low molecular weight heparin.

Exclusion Criteria:

* prior treatment for recurrent, metastatic, or unresectable gastroesophageal or gastric adenocarcinoma
* other concurrent anticancer therapy
* other malignancy within past three years except basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer known central nervous system metastases or carcinomatous meningitis.
* interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.
* \> grade 2 sensory peripheral neuropathy.
* uncontrolled seizure disorder, active neurological disease, or known CNS disease.
* significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment.
* history of hypertensive crisis or hypertensive encephalopathy
* abdominal fistula, gastrointestinal bleeding, or intra-abdominal abscess within the 6 months prior to study enrollment.
* core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.
* major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study.
* recent arterial thrombotic events including stroke or TIA within 6 months prior to study enrollment.
* serious or non-healing wound, ulcer or bone fracture.
* active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices).

Primary outcomes:
measure: Progression Free Survival
timeFrame: Upon completion of study, up to 3 years
Secondary outcomes:
measure: Overall Tumor Response Rate by RECIST Criteria
timeFrame: Upon completion of study
measure: Overall Survival
timeFrame: Upon completion of study, up to 3 years
Other outcomes:
Locations:
city: Hamden
country: United States
facility: Medical Oncology & Hematology PC
state: Connecticut
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Jill Lacy, M.D.
role: PRINCIPAL_INVESTIGATOR
References: